<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605642</url>
  </required_header>
  <id_info>
    <org_study_id>ZOBINF1505</org_study_id>
    <secondary_id>C1231002</secondary_id>
    <nct_id>NCT02605642</nct_id>
  </id_info>
  <brief_title>Post-Marketing Use Of Inflectra (Infliximab) For Standard Of Care Treatment Of Rheumatoid Disease Who Are Naïve To Biologics Or Switched From Remicade™</brief_title>
  <acronym>PERSIST</acronym>
  <official_title>Persist: Prospective Observational Cohort Study To Assess Persistence Of Inflectra(tm) (Infliximab) In Patients With Rheumatoid Diseases Who Are Either Naive To Biologics Or Switched From Stable Remicade(tm) (Infliximab)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess persistence of Inflectra in patients with Rheumatoid Disease (Rheumatoid arthritis
      [RA], ankylosing spondylitis [AS], and psoriatic arthritis [PsA]) who are naive to biologics
      or are switching over from stable Remicade to Inflectra. The main objectives of the study
      are:

        -  To evaluate real-life drug persistence in RA, AS, and PsA patients who are either
           initiated with Inflectra™ as their first biologic, or who are switched from stable
           Remicade™

        -  To characterise the patient populations and drug usage patterns of RA, AS, and PsA
           patients who are either initiated with Inflectra™ as their first biologic, or who are
           switched from stable Remicade™

        -  To assess the safety of Inflectra™ in RA, AS, and PsA patients who are either initiated
           with Inflectra™ as their first biologic, or who are switched from stable Remicade for up
           to 2 years
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted according to GCP guidelines, and data sources will be validated.
      The source data will consist of medical records, physician questionnaires, and patient
      questionnaires. Data for the study will be entered into an electronic data capture system.
      Questionnaires will be completed on electronic tablets. The study is a one year enrollment
      period with a two years follow-up period. The study plans to enroll patients throughout
      Canada and Europe.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 10, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to discontinuation from study drug in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients</measure>
    <time_frame>Approximately every 2 months, with a total follow-up of 2 years</time_frame>
    <description>In patients who are either initiated with Inflectra™ as their first biologic, or who are switched from stable Remicade™</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for study discontinuation</measure>
    <time_frame>Approximately every 2 months, with a total follow-up of 2 years</time_frame>
    <description>Using predefined categories pertaining to efficacy, safety and tolerability. In patients who are either initiated with Inflectra™ as their first biologic, or who are switched from stable Remicade™</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of disease duration in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patient</measure>
    <time_frame>Approximately every 2 months, with a total follow-up of 2 years</time_frame>
    <description>In patients who are either initiated with Inflectra™ as their first biologic, or who are switched from stable Remicade™</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of surgery status in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patient</measure>
    <time_frame>Approximately every 2 months, with a total follow-up of 2 years</time_frame>
    <description>In patients who are either initiated with Inflectra™ as their first biologic, or who are switched from stable Remicade™.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of drug dose in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patient</measure>
    <time_frame>Approximately every 2 months, with a total follow-up of 2 years</time_frame>
    <description>In patients who are either initiated with Inflectra™ as their first biologic, or who are switched from stable Remicade™.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with serious adverse events (SAE) as a measure of safety of Inflectra™ in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>In patients who are either initiated with Inflectra™ as their first biologic, or who are switched from stable Remicade™</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Adverse events of special interest (AESI) as a measure of safety of Inflectra™ in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>In patients who are either initiated with Inflectra™ as their first biologic, or who are switched from stable Remicade™.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of drug frequency in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patient</measure>
    <time_frame>Approximately every 2 months, with a total follow-up of 2 years</time_frame>
    <description>In patients who are either initiated with Inflectra™ as their first biologic, or who are switched from stable Remicade™.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of concomitant medication use in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patient</measure>
    <time_frame>Approximately every 2 months, with a total follow-up of 2 years</time_frame>
    <description>In patients who are either initiated with Inflectra™ as their first biologic, or who are switched from stable Remicade™.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Infliximab effectiveness in rheumatoid arthritis patient by Disease Activity Score (DAS28)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Infliximab effectiveness in psoriatic arthritis patient by DAS28 score</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Infliximab effectiveness in ankylosing spondylitis patients by Ankylosing Spondylitis Disease Activity Score (ASDAS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of levels of pain, discomfort and fatigue in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis patients using a Visual Analog Scale (VAS: 0-10)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>VAS Range for pain: No pain to very severe pain; Discomfort: Easy to impossible; Fatigue: Not active to very active</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in Ankylosing Spondylitis patients</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bath Ankylosing Spondylitis Functional Index (BASFI) in ankylosing spondylitis patients</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient reported outcome measure by Health Assessment Questionnaire Disability Index (HAQ-DI) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient reported outcome measure by Short Form 12-version 2 (SF-12v2) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient reported outcome measure by EuroQol 5-Dimensions 3-levels (EQ-5D-3L) rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Physician Global Assessment using Visual Analog Scale (VAS: 0-10)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>VAS range: 0 - 10 (No disease activity to Extremely active)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess the immunogenicity profile (therapeutic drug monitoring)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measurement of Anti-Drug antibodies to infliximab and infliximab trough levels using a validated ELISA kit</description>
  </other_outcome>
  <enrollment type="Actual">351</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab (Inflectra™)</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target study population will include biologic naive rheumatoid arthritis, ankylosing
        spondylitis, and psoriatic arthritis patients receiving Inflectra™ or those switched to
        Inflectra™ from stable treatment with Remicade™.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged ≥18 years old at the time of enrollment

          2. Patients who are prescribed Inflectra or Remicade for the treatment of rheumatoid
             arthritis, ankylosing spondylitis, and psoriatic arthritis prescribed according to the
             corresponding summary of product characteristics (SmPC and Product Monograph) as
             determined by the investigator

        Exclusion Criteria:

          1. Any reported contraindications for Inflectra according to the SmPC or Product
             Monograph

          2. Known hypersensitivity (including severe, acute infusion reactions) to infliximab, its
             excipients or other murine proteins, at the time of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MHAT Trimontium OOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Kaspela EOOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center VII Sofia OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucere Skin Dermatology &amp; Laser Clinic</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>TX6 0N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Juris Lazovskis Inc.</name>
      <address>
        <city>Sydney</city>
        <state>Nova Scotia</state>
        <zip>B1S 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Waterside Clinic</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adachi Medicine Professional Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K-W Musculoskeletal Research Inc</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 5N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Y. Liu Medicine Professional</name>
      <address>
        <city>Milton</city>
        <state>Ontario</state>
        <zip>L9T 3Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Imaging Associates</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakville Rheumatology &amp; Osteoporosis</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur Karasik Medicine Professional Corporation</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9C 5N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Sabeen Anwar Medicine Professional Corporation</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal - Notre-Dame Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rhumatologie de l'Est</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 8W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Musculo-Squelettique</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe de Recherche en Rhumatologie et Maladies Osseuses (GRMO)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie MUDr. Klara Sirova s.r.o.</name>
      <address>
        <city>Ostrava</city>
        <zip>70200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Prague 2</city>
        <zip>12850</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Steglitz</name>
      <address>
        <city>Berlin</city>
        <zip>12163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologisches MVZ Dresden GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Gesundheitszentrum Elmshorn</name>
      <address>
        <city>Elmshorn</city>
        <zip>25335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Praxis Dr. med. Kaufmann</name>
      <address>
        <city>Ludwigsfelde</city>
        <zip>14974</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Praxis Dr. med. Kühne</name>
      <address>
        <city>Ludwigsfelde</city>
        <zip>39340</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Prof.Dr. med. Herbert Kellner</name>
      <address>
        <city>Muenchen-Nymphenburg</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologie Dr. Martin Welcker GmbH</name>
      <address>
        <city>Planeg</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumahaus Potsdam GbR</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis Rheumatologie Dr. med. R.Jochen Walter</name>
      <address>
        <city>Rendsburg</city>
        <zip>24768</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Heraklion, Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario a Coruna</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salisbury NHS Foundation Trust - Salisbury District Hospital</name>
      <address>
        <city>Sailsbury</city>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflectra</keyword>
  <keyword>Infliximab</keyword>
  <keyword>Observational</keyword>
  <keyword>Remicade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

